Table 2

Demographics and baseline characteristics of non-ocular melanoma patients treated with indoximod+pembrolizumab (N=89; efficacy population)

Characteristicn (%)
Median age (range), years61.5 (27–88)
Male56 (63)
Caucasian85 (96)
Disease stage
 IIIB (unresectable)4 (4)
 IIIC (unresectable)6 (7)
 IV79 (89)
 M1a25 (28)
 M1b17 (19)
 M1c37 (42)
LDH above ULN22 (25)
ECOG 0 or 189 (100)
Prior therapy
 Radiation14 (16)
 Systemic*16 (18)
  • *Includes BRAF and IL-1, but treatment with checkpoint inhibitor was not allowed per exclusion criteria.

  • BRAF, 8-rat proto-oncogene, serine/threonine kinase; ECOG, Eastern Cooperative Oncology Group; IL-1, interleukin-1; LDH, lactate dehydrogenase; ULN, upper limit of normal.